A Morganti
Overview
Explore the profile of A Morganti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tocci G, Ferrucci A, Pontremoli R, Ferri C, Rosei E, Morganti A, et al.
J Hum Hypertens
. 2015 Feb;
29(11):696-701.
PMID: 25673112
This analysis is aimed to determine blood pressure (BP) levels and BP control rates in a large population of hypertensive patients in Italy. Data were taken from two large and...
2.
Morganti P, Morganti G, Morganti A
Nanotechnol Sci Appl
. 2013 Nov;
4:123-9.
PMID: 24198491
Chitin, obtained principally from crustacean waste, is a sugar-like polymer that is available at low cost. It has been shown to be bio- and ecocompatible, and has a very low...
3.
Annibali R, Caponi L, Morganti A, Manna M, Gabrielli O, Ficcadenti A
Minerva Pediatr
. 2013 Sep;
65(5):487-96.
PMID: 24056375
Aim: Our study aim is the evaluation of long-term effects of hematopoietic stem cell transplantation on Italian patients with severe Hunter syndrome. Methods: Four boys, suffering from Hunter syndrome, severe...
4.
Rossi G, Seccia T, Gallina V, Muiesan M, Leoni L, Pengo M, et al.
J Hum Hypertens
. 2012 Jun;
27(3):158-63.
PMID: 22718050
Primary aldosteronism (PA) is the most common endocrine form of hypertension and may carry an increased risk of atrial flutter or fibrillation (AFF). The primary goal of this multicentre cohort...
5.
Cuspidi C, Sala C, Negri F, Mancia G, Morganti A
J Hum Hypertens
. 2011 Nov;
26(6):343-9.
PMID: 22113443
Left-ventricular hypertrophy (LVH) is a cardinal manifestation of hypertensive organ damage associated with an increased cardiovascular (CV) risk. We reviewed recent literature on the prevalence of LVH, as assessed by...
6.
Rossi G, Seccia T, Miotto D, Zucchetta P, Cecchin D, Calo L, et al.
J Hum Hypertens
. 2011 Jul;
26(8):507-16.
PMID: 21716318
It is unclear whether revascularization of renal artery stenosis (RAS) by means of percutaneous renal angioplasty and stenting (PTRAS) is advantageous over optimal medical therapy. Hence, we designed a randomized...
7.
Tomasoni L, Sitia S, Borghi C, Cicero A, Ceconi C, Cecaro F, et al.
Autoimmun Rev
. 2010 Aug;
9(12):840-4.
PMID: 20678593
A large body of evidence indicates that endothelial dysfunction is a characteristic of patients with arterial hypertension. As functional abnormalities lead to impaired endothelium-dependent vasodilation, this early step of atherogenesis...
8.
Cuspidi C, Negri F, Giudici V, Capra A, Muiesan M, Agabiti-Rosei E, et al.
J Hum Hypertens
. 2009 Nov;
24(6):395-402.
PMID: 19907436
Little information is available about the burden of hypertension on echo-lab activity in current practice. The aim of the present nation-wide survey in outpatient echo-labs was to investigate the prevalence...
9.
Lonati C, Morganti A
Pediatr Med Chir
. 2009 Sep;
31(3):137-9.
PMID: 19739495
No abstract available.
10.
Denton C, Pope J, Peter H, Gabrielli A, Boonstra A, Van den Hoogen F, et al.
Ann Rheum Dis
. 2007 Dec;
67(9):1222-8.
PMID: 18055477
Objectives: This study investigated the long-term effects of bosentan, an oral endothelin ET(A)/ET(B) receptor antagonist, in patients with pulmonary arterial hypertension (PAH) exclusively related to connective tissue diseases (CTD). Methods:...